The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results ...

Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal Phase 3 PURPOSE 2 ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Gilead Sciences demonstrated positive momentum on the NASDAQ, with shares climbing 0.6 percent to $91.88. This upward trajectory is primarily attributed to groundbreaking results from clinical trials ...

Global HIV rates drop 20 but challenges persist in ending AIDS by 2030 Explore breakthroughs like lenacapavir prevention ...

A vaccination with the drug lenacapavir offers an effective protection against a HIV infection, according to newly published ...

Expect scattered rain showers. The low will be 66°. Moderate air quality (51-100) Primary pollutant O₃ 86 μg/m³ Amount of moisture present in the air relative to the maximum amount of moisture the air ...

In addition, we kept open the possibility that the ETF will continue to rise and could reach around 108.45. To see how we ...

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December: 7th Annual Evercore ...

For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including ...